Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AKRO vs LFCR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AKRO Captures Overall Composite Edge (60.0 BUY vs 58.2 HOLD), While LFCR Leads 4–2 on Growth & Valuation Pillars

AKRO Overall Winner 6-Pillar Tally: AKRO 2 – 4 LFCR Matrix Metrics: AKRO 8 – 2 LFCR

As of Nov 20, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over Lifecore Biomedical, Inc. (LFCR) on higher Unified Composite conviction (60.0/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 8–2 (led by Growth & Scale, Profitability & Quality), while LFCR wins 4–2 across the 6-pillar growth and valuation breakdown. AKRO trades at $54.65 (N/M Forward P/E, 0.0% operating margin) versus LFCR at $6.39 (8.7x Forward P/E, -6.2% operating margin).

  • Growth vs. Quality Trade-Off: AKRO earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. LFCR 58.2/100 HOLD) and 0.90β · 2% Vol risk profile, whereas LFCR leads top-line expansion (-18.6% YoY revenue growth, 2.66x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKRO vs LFCR
AKRO NASDAQ Head-to-Head Winner
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91
LFCR NASDAQ
Lifecore Biomedical, Inc. Common Stock
Pharmaceutical Preparations
$6.39
+0.31% 1D
Market Cap $241.5M
TTM Revenue $106M
Forward P/E 8.7x
Beta / 30D Vol 0.44β · 9% Vol
Unified Composite Score
58.2 / 100 HOLD
Tech 52.0 Fund 55.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (15.0% over 20 days), RSI 59
RSI-14: 59.1 · SMA20: $6.41 · SMA50: $6.01

6-Pillar Scorecard Institutional Category Breakdown (AKRO 2 – 4 LFCR)

Columns: Metric · AKRO · LFCR
1. Valuation Multiples LFCR
Forward P/E N/M 8.7x
Trailing P/E N/M 8.7x
PEG Ratio N/M 2.66x
EV / Revenue N/M 3.6x
2. Growth & Scale AKRO
Revenue Growth (YoY) +0.0% -18.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $106M
Market Cap $4.5B $241.5M
3. Profitability & Quality AKRO
Gross Margin N/A 27.5%
Operating Margin 0.0% -6.2%
Net Profit Margin 0.0% -66.8%
Return on Equity (ROE) -34.5% -76.4%
4. Balance Sheet & Cash Flow LFCR
Cash Generation (TTM) N/A $6.9M
Cash Flow Margin N/A 6.5%
Net Cash / Leverage $11.95 Book/Sh · -34.5% ROE $138M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LFCR
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 7.3% (30th %ile) 0.0% (<1st %ile)
Put/Call OI Skew N/A 0.77x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat LFCR
OpEx & R&D Intensity N/A 33.7% of Rev ($36M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Pharmaceutical Preparations Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKRO (8) vs LFCR (2)
Institutional Metric AKRO LFCR Criterion Row Edge
Market Capitalization
Scale
$4.5B $241.5M Larger Scale AKRO
Trailing P/E Ratio
Valuation
N/M 8.7x Lower Multiple LFCR
Forward P/E Ratio
Valuation
N/M 8.7x Lower Multiple LFCR
Revenue Growth (YoY)
Growth
+0.0% -18.6% Higher Growth AKRO
Operating Margin (TTM)
Profitability
0.0% -6.2% Higher Margin AKRO
Net Profit Margin
Profitability
0.0% -66.8% Higher Margin AKRO
Return on Equity (ROE)
Capital Efficiency
-34.5% -76.4% Higher ROE AKRO
52-Week Range Position
Momentum
90% ($21–$58) 52% ($4–$9) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
0.90β · 2% Vol 0.44β · 9% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 58.2 / 100 (HOLD) Higher Composite AKRO
Trailing 12M Revenue (USD)
Operating Scale
N/A $106M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 27.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 2.66x PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.95 Book/Sh · -34.5% ROE) $6.9M ($138M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AKRO +0.3 pp
AKRO: +0.57% · LFCR: +0.27%
3M Horizon AKRO +0.3 pp
AKRO: +0.57% · LFCR: +0.27%
6M Horizon AKRO +0.3 pp
AKRO: +0.57% · LFCR: +0.27%
1Y Horizon AKRO +0.3 pp
AKRO: +0.57% · LFCR: +0.27%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs LFCR. Trailing 12-month operating profitability (AKRO 0.0% vs LFCR -6.2%) and valuation multiples (AKRO N/M vs LFCR 8.7x Forward P/E) are benchmarked directly in Pillar 4 below.

AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M
LFCR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$106M
Gross Margin27.5%
Op. Margin-6.2%
ROE / Fwd P/E-76.4% · 8.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LFCR CONSOLIDATION
38d in phase · OBV NEUTRAL
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew 0.77x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LFCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LFCR Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $241.5M market capitalization and -6.2% operating margin.
OpEx & R&D Reinvestment 33.7% of Rev ($36M)
90D Engineering Disclosures 0 Published

Investor FAQ AKRO vs LFCR Key Questions & Quantitative Answers

As of Nov 20, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over Lifecore Biomedical, Inc. (LFCR) on higher Unified Composite conviction (60.0/100 BUY vs. 58.2/100 HOLD) after splitting the core matrix 8–2 (led by Growth & Scale, Profitability & Quality), while LFCR wins 4–2 across the 6-pillar growth and valuation breakdown. AKRO trades at $54.65 (N/M Forward P/E, 0.0% operating margin) versus LFCR at $6.39 (8.7x Forward P/E, -6.2% operating margin). Growth vs. Quality Trade-Off: AKRO earns the overall head-to-head edge with a stronger Unified Composite Score (60.0/100 BUY vs. LFCR 58.2/100 HOLD) and 0.90β · 2% Vol risk profile, whereas LFCR leads top-line expansion (-18.6% YoY revenue growth, 2.66x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.

AKRO leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LFCR at -18.6% YoY revenue growth and +0.0% YoY earnings growth on $106M TTM revenue (27.5% gross margin, -6.2% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus $106M for LFCR. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus 33.7% of Rev ($36M) (0 disclosures) for LFCR.

LFCR screens cheaper on headline valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas LFCR trades at 8.7x Forward P/E, 8.7x Trailing P/E, 2.66x PEG, and 3.6x EV/Revenue (6.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus LFCR (-76.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, LFCR carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.44β · 9% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.